You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias

    SBC: Path Biotech, LLC            Topic: NIA

    PROJECT SUMMARY/ABSTRACT In response to National Institute on Aging's (NIA) strategic plan and PAS-19-317, we propose novel therapeuticsto treat Alzheimer disease and related dementias (ADRDs). We have developed novel combinations of three natural product compounds, which modulate complementary pathways in multiple types of CNS cells (i.e., neurons, microglia) associated with AD pathology. These c ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. 3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring

    SBC: Axioforce LLC            Topic: NIBIB

    PROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a new aspiration catheter solution for the treatment of large and medium vessel occlusions

    SBC: ANEUVAS TECHNOLOGIES INC            Topic: 104

    Project Summary/Abstract Stroke is the leading cause of serious long-term disability and accounts for 4.6 million disabled people in the United States. Stroke-related costs total over $46 billion in the United States each year.1 Of the nearly 800,000 Americans who have a stroke per year, 87% experience ischemic stroke1, of which 49%-86% are attributed to either large vessel occlusions (LVO) or med ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Biomarkers for Brain Resetting as an Assistive Tool in the Treatment of Status Epilepticus

    SBC: Epifocus LLC            Topic: 104

    The proposed phase-I STTR research is an interdisciplinary effort to develop more effective clinical management of Status Epilepticus (SE) in collaboration with one of the leading neurological institutes in the world, the Barrow Neurological Institute in Phoenix, Arizona. SE is a life-threatening neurological emergency that can occur without warning and is characterized by recurrent seizures witho ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Increasing IDeA state Biomedical Entrepreneurship via Ecosystem, Enterprises and Experts

    SBC: Insitehub LLC            Topic: NIGMS

    Summary The proposed DE iRED program consists of university and private sector partnerships to deliver a comprehensive program that will engage and support biomedical innovators in the early stages of technology commercialization by addressing key bottlenecks in the startup process as identified both in the solicitation and by the DRIVEN Accelerator Hub. According to DRIVEN’s Voice of Customer i ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Small Molecule Inhibitor of Fortilin for Atherosclerosis Treatment and Prevention

    SBC: FORTISCIENCE, INC.            Topic: NHLBI

    Project Summary Project Title: Development of a Small Molecule Inhibitor of Fortilin for Atherosclerosis Treatment and Prevention. Atherosclerosis affects more than 18 million Americans and is a major cause of cardiovascular diseases and acute cardiovascular events, such as heart attack and stroke. Current interventions include changes to diet and exercise, smoking cessation, and treatment with st ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.

    SBC: Shift Pharmaceuticals Holdings, Inc.            Topic: 106

    Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.

    SBC: Antiger Therapeutics Inc.            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT The mission of Antiger Therapeutics Inc. is to develop novel immunotherapies for transplant recipients to improve long-term graft outcomes and minimize adverse effects. Antibody-mediated rejection (AMR) is a leading cause of graft loss, with over 3000 new cases per year in the United States and estimated market size of $90 million. However, this estimate is likely to under ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government